Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02390427
Title Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Otto Metzger, MD
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.